The actual benefit of PERJETA in combination with Herceptin and docetaxel in its Marketing Authorisation indication is substantial.
Clinical Added Value
moderate
PERJETA in combination with trastuzumab and docetaxel provides a moderate improvement in actual benefit (level III) in the management of HER2-positive metastatic or locally recurrent unresectable breast cancer which has not previously been treated with anti-HER2 therapy or chemo‑therapy for the metastatic disease.
Listen
